title: Re: Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress?
authors.forename: M H
authors.initials: MH
authors.lastname: Gail
authors.forename: J P
authors.initials: JP
authors.lastname: Costantino
authors.forename: J
authors.initials: J
authors.lastname: Bryant
authors.forename: R
authors.initials: R
authors.lastname: Croyle
authors.forename: L
authors.initials: L
authors.lastname: Freedman
authors.forename: K
authors.initials: K
authors.lastname: Helzlsouer
authors.forename: V
authors.initials: V
authors.lastname: Vogel
mesh_terms: D001741:Black or African American / Q000706:statistics & numerical data*; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control*; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D012306:Risk; D018570:Risk Assessment; D013629:Tamoxifen / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology
chemical_list: D016588:Anticarcinogenic Agents; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen